<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="579">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00160628</url>
  </required_header>
  <id_info>
    <org_study_id>N01099</org_study_id>
    <nct_id>NCT00160628</nct_id>
  </id_info>
  <brief_title>Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy</brief_title>
  <official_title>A Korean Open-label, Multi-center, Community-based Trial Assessing the Efficacy and Safety of Levetiracetam as Adjunctive Therapy in Adult Subjects With Uncontrolled Partial Epilepsy for Bridging Purpose With a Similar Study on Caucasian Epileptic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Korean open-label, community-based trial assessing the efficacy and safety of
      levetiracetam as adjunctive therapy in partial epilepsy.

      Similarity with a similar study conducted in Caucasian epileptic subjects will be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>To evaluate efficacy of levetiracetam in community based practice (seizure frequency per week over 16 weeks).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess safety of levetiracetam</measure>
  </secondary_outcome>
  <enrollment>100</enrollment>
  <condition>Epilepsy, Partial</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with epilepsy experiencing partial seizures, whether or not secondarily
             generalized.

          -  Subjects must present between 3 and 42 partial seizures over the three months prior
             to protocol Visit 1.

          -  Use of one (1), but no more than two (2) concomitant marketed AEDs at the time of
             trial entry.

        Exclusion Criteria:

          -  Subjects on felbamate with less than 18 months exposure.

          -  Subjects on vigabatrin, whose visual field has not been assessed as per
             recommendation of the manufacturer, i.e. every 6 months.

          -  Presence of known pseudoseizures within the last year.

          -  Presence of progressive cerebral disease, any other progressively degenerative
             neurological disease, or any cerebral tumors.

          -  Uncountable seizures (clusters) or history of convulsive status epilepticus within
             the last five years.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>UCB Pharma</affiliation>
  </overall_official>
  <link>
    <url>http://www.ucb.com/_up/ucb_com_patients/documents/N01099_CSS_20060206.pdf</url>
    <description>Clinical Study Summary on UCB.com</description>
  </link>
  <results_reference>
    <citation>Heo K, Lee BI, Yi SD, Huh K, Kim JM, Lee SA, Shin DJ, Song HK, Lee SK, Kim JY, Lu S, Dubois C, Tonner F. Efficacy and safety of levetiracetam as adjunctive treatment of refractory partial seizures in a multicentre open-label single-arm trial in Korean patients. Seizure. 2007 Jul;16(5):402-9. Epub 2007 Mar 19.</citation>
    <PMID>17369059</PMID>
  </results_reference>
  <verification_date>February 2010</verification_date>
  <lastchanged_date>November 25, 2013</lastchanged_date>
  <firstreceived_date>September 8, 2005</firstreceived_date>
  <keyword>Epilepsy</keyword>
  <keyword>Partial Onset Seizures</keyword>
  <keyword>Keppra</keyword>
  <keyword>Levetiracetam</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsies, Partial</mesh_term>
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
